Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Temasek-backed Manipal Health gets approval for India IPO, eyes July listing - The Edge Malaysia
Temasek-backed Manipal Health gets approval for India IPO, eyes July listingThe Edge Malaysia
Manipal Health gets SEBI approval for up to $1.2 billion IPO, listing likely in late July
Manipal Health Enterprises has secured regulatory approval from the Securities and Exchange Board of India (SEBI) to proceed with its initial public offering, according to sources familiar with the development. The hospital operator is targeting a market debut in late July or early August, subject to prevailing market conditions. The company had filed IPO papers in March to raise up to $1.2 billion, positioning the issue among the largest healthcare listings in India. The planned offering comes at a challenging time for the primary market, with geopolitical tensions and sustained foreign portfolio outflows weighing on investor sentiment. Despite market volatility, the listing is expected to be closely tracked given growing demand for healthcare services and Manipal Health's scale in the hospital sector.
Leo International Precision Health Share Price Today | ETR: LEOW - Investing.com India
Leo International Precision Health Share Price Today | ETR: LEOWInvesting.com India
Mother Sparsh sees up to 40% growth as baby-care boom defies consumer slowdown
Mother Sparsh anticipates a robust 30-40% revenue surge this year, defying broader consumption slowdowns. Indian parents are prioritizing their babies' health and well-being, investing in premium, 'no nasties' products. Leveraging ITC's extensive distribution, the brand aims to expand its reach beyond online channels into smaller cities, tapping into a growing demand for trusted, scientifically-backed baby care solutions.
Zydus partners with Guardant Health and Apollo Hospitals to introduce Shield MCD in India
Zydus Lifesciences and Guardant Health, Inc., a leading precision oncology company, have an exclusive agreement to make the Shield Multi-Cancer Detection (MCD) test available in India, for which Zydus has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to offer the test in the territory.
Zydus Lifesciences ties up with Apollo Hospitals to offer Shield multi-cancer detection test
Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield multi-cancer detection test in India, made possible through an agreement with Guardant Health. This innovative blood test can identify signals for multiple cancer types in individuals aged 45 and above. The collaboration aims to enhance early cancer detection and improve patient outcomes across the nation, making advanced screening more accessible.
Red Bull, Campa, Monster and other beverage cos get notices over 'energy drink' claims
India's food regulator, FSSAI, has cracked down on major beverage brands like Red Bull and Monster, issuing notices for using the 'energy drink' label and making health-related claims. The authority states that no such category is recognized under current food safety laws. Companies are warned against promotional statements about boosting energy or focus, as these functional claims are not permitted for food products, aiming to prevent misleading branding.
Bank of Baroda to pay $600 million to settle NMC Health insolvency claims
Bank of Baroda has agreed to a $600 million settlement with administrators of the insolvent NMC Health Plc. The bank faced allegations of gross negligence, failing to conduct proper due diligence, and allowing fraudulent transactions without adhering to anti-money laundering and KYC norms. This payout, significantly exceeding its reported exposure, aims to resolve claims from NMC Health and its affiliates, stemming from a fraud discovered between 2012-2020.
Bank of Baroda to pay $600 million to settle NMC Health insolvency claims
Bank of Baroda has agreed to a $600 million settlement with administrators of the insolvent NMC Health Plc. The bank faced allegations of gross negligence, failing to conduct proper due diligence, and allowing fraudulent transactions without adhering to anti-money laundering and KYC norms. This payout, significantly exceeding its reported exposure, aims to resolve claims from NMC Health and its affiliates, stemming from a fraud discovered between 2012-2020.
Govt brings stem cell, gene therapies under central licensing framework
India's drug regulations have been updated to include advanced treatments like cell, stem cell, gene therapies, and xenografts under central licensing. This move aims to bolster oversight for these complex, evolving medical technologies, ensuring patient safety and uniform standards nationwide. The amendment signifies a commitment to public health while fostering innovation and faster adoption of cutting-edge healthcare solutions.
Elevance Health stock hits 52-week high at 427.07 USD By Investing.com - Investing.com India
Elevance Health stock hits 52-week high at 427.07 USD By Investing.comInvesting.com India
Bank of Baroda pays $600 million to settle NMC Health litigation
The settlement resolves all claims between the parties without any admission of liability or wrongdoing by the bank, according to the filing. Apart from the settlement amount, the terms of the agreement remain confidential.